FDA Approves Gilead’s Trodelvy, Alone and With Merck’s Keytruda, in First-Line Metastatic TNBC
oncodaily - Decision delivers the first ADC-based regimens for previously untreated triple-negative breast cancer across PD-L1 status, a PD-L1-positive Keytruda combination plus a monotherapy option for immunotherapy-ineligible patients. The U.S. Food and […]
AI Summary: The FDA approved sacituzumab govitecan (Trodelvy) as both monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of metastatic triple‑negative breast cancer, expanding options for a hard-to-treat population. Regulators cited clinical benefit in appropriate patients, reshaping treatment sequencing and payer discussions.
FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC
esmo -
AI Summary: Regulators have approved datopotamab deruxtecan for patients with unresectable or metastatic triple‑negative breast cancer, offering a new targeted option where few exist. The decision follows trial evidence of meaningful anti‑tumor activity and expands the treatment toolkit for aggressive TNBC subtypes, with clinicians weighing sequencing and toxicity management.
Medical Journal Retracts Study Claiming Cancer Therapy Is More Effective When Given in the Morning
Rebecca Robbins / nytimes - In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors “no longer have confidence in the integrity of the results.”
AI Summary: A high‑profile medical journal retracted a paper that claimed cancer immunotherapy is significantly more effective when administered in the morning. The reversal follows scrutiny over methods and data integrity, prompting clinicians to pause any scheduling changes until robust evidence actually materializes.
Bruce Levine: Ten-Year Outcomes Reinforce the Durability of CD19 CAR T-Cell Therapy
oncodaily - Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, shared a post on X: “NEW – Ten-Year Outcomes after CAR T-Cell Therapy for […]
AI Summary: Long‑term data reveal that CD19 CAR‑T therapy produces durable remissions in a subset of B‑cell lymphoma patients, with ten‑year outcomes reinforcing the treatment's long‑term benefit for some. The findings bolster CAR‑T’s curative potential while underscoring the need to identify who will enjoy durable responses.
AACR Report on Cancer Disparities and Health Equity
oncodaily - American Association for Cancer Research (AACR) shared a post on LinkedIn: “The AACR Cancer Disparities Progress Report 2026 is now available. The report outlines the myriad factors that drive and […]
AI Summary: The American Association for Cancer Research released a progress report detailing persistent gaps in cancer outcomes across race, ethnicity, socioeconomic status and geography. It documents uneven access to screening, trials and treatments, calls for targeted funding, workforce diversity and policy fixes, and urges measurable equity goals—because apparently pointing out the problem is step one.
- AACR report release and leadership outreach (4)
- Policy push: briefings, funding calls, and trial equity (4)
AACR report release and leadership outreach
Policy push: briefings, funding calls, and trial equity
Jeremy Clarkson’s Prostate Cancer Story: Early Detection, Treatment, and Remission
oncodaily - Jeremy Clarkson has revealed that he was diagnosed with an aggressive form of prostate cancer that was caught early. The broadcaster shared the diagnosis in the final episodes of Clarkson’s […]
AI Summary: Jeremy Clarkson publicly revealed an aggressive prostate cancer diagnosis, underwent early detection and treatment, and is now in remission. The case highlights the value of prompt screening and modern therapies — and proves even TV personalities can be very boringly human when faced with routine medicine.
Early-onset cancers are on the rise: Knowing family history is crucial
medicalxpress - In the U.S., more than a dozen kinds of cancer are on the rise in adults under 50. Among these early-onset cancers, colorectal and breast cancers have increased the most, and colorectal cancer is now the deadliest cancer for Americans ages 18 to 49.
AI Summary: New analyses show early‑onset cancers are increasing and reinforce that detailed family history remains a key tool for risk assessment and targeted screening. Experts urged clinicians and health systems to prioritize family‑history collection and cascade testing to catch at‑risk individuals sooner and reduce preventable morbidity.
- Breast cancer risk: AI tools, polygenic scores, prevention (5)
- Colorectal cancer: rising cases and screening gaps worldwide (6)
- Faster biological aging linked to early-onset cancer rise (5)
- Inherited cancer risk and genomics driving early diagnoses (6)
- All Other Stories
Breast cancer risk: AI tools, polygenic scores, prevention
Colorectal cancer: rising cases and screening gaps worldwide
Faster biological aging linked to early-onset cancer rise
Inherited cancer risk and genomics driving early diagnoses
All Other Stories
Hathal Haddad: 28 Days Until Brachytherapy Awareness Day 2026
oncodaily - Hathal Haddad, Head of Interventional Radiotherapy Unit at the Department of Radiation Oncology at University Hospital Tübingen, shared a post on LinkedIn: “28 Days Until Brachytherapy Awareness Day 2026 The Original Adaptive […]
AI Summary: Radiation oncologists and advocates are publicly gearing up for Brachytherapy Awareness Day, using countdowns and outreach to raise awareness of image‑guided and salvage brachytherapy techniques. The push emphasizes education, patient access and the specialty’s role in targeted cancer treatment — all packaged with the predictable mix of pride and promotional zeal.
- Countdown and technique spotlights ahead of Brachytherapy Awareness Day (4)
- Guidelines, re-irradiation debates and professional meeting updates (4)
Countdown and technique spotlights ahead of Brachytherapy Awareness Day
Guidelines, re-irradiation debates and professional meeting updates
Purdue Researchers Develop Next-Generation Automated Platform to Accelerate Drug Discovery – Purdue Institute for Cancer Research
oncodaily - Purdue Institute for Cancer Research shared a post on LinkedIn: “Purdue researchers, including Nicolás Morato and R. Graham Cooks, have developed a next-generation platform that integrates chemical synthesis, biological testing, […]
AI Summary: Purdue researchers unveiled an automated mass‑spectrometry platform that compresses key steps of small‑molecule drug discovery into a matter of hours, promising faster lead identification and screening. The system couples high‑throughput chemistry with rapid readouts to accelerate iteration cycles, potentially shrinking timelines and costs for early oncology drug development — welcome news for impatient scientists.
More Americans Are Surviving Cancer. But the Mental Health Challenges Can Persist.
Natalie Krebs, Iowa Public Radio / kffhealthnews - Amid advancements in treatment and screening, more Americans are surviving the disease. But many are left with psychological scars, such as lingering anxiety and depression.
AI Summary: New analyses show cancer survival rates have improved, yet many survivors continue to face persistent mental‑health burdens including anxiety, depression and social isolation. Experts call for integrated psychosocial care, routine screening and long‑term support services to address survivorship needs, arguing that beating cancer shouldn’t mean signing up for a second, emotional marathon.
- MASCC 2026: Global spotlight on supportive cancer care (4)
- Practical survivorship needs: rehab, fertility, cardiac care (5)
- Psychosocial oncology programs, research and education initiatives (4)
- Rising survivorship, rising mental‑health burdens (5)
- All Other Stories
MASCC 2026: Global spotlight on supportive cancer care
Practical survivorship needs: rehab, fertility, cardiac care
Psychosocial oncology programs, research and education initiatives
Rising survivorship, rising mental‑health burdens
All Other Stories
Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment
esmo - Findings from the MajesTEC-9 study
AI Summary: Clinical data show teclistamab significantly improves survival for patients with multiple myeloma after one to three prior therapies. Those results have ignited discussions about moving the bispecific antibody earlier in treatment algorithms and prompted labs and clinicians to reassess sequencing strategies across relapsed and refractory myeloma.
FDA approves Welireg with pembrolizumab for renal cell carcinoma
medicalxpress - The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear ce…
AI Summary: The FDA cleared Welireg (belzutifan) in combination with pembrolizumab for adjuvant treatment of renal cell carcinoma at high risk of recurrence after surgery. The approval expands belzutifan’s indications, offering a new post‑nephrectomy option intended to lower recurrence risk and reflecting regulators’ willingness to endorse targeted therapy combinations in kidney cancer.
Cervical cancer deaths have plummeted thanks to HPV vaccine
newscientist - We already know the vaccine against human papillomavirus, or HPV, greatly reduces infections and cases of cervical cancer, and now we have the first evidence it prevents deaths too
AI Summary: New population data show the HPV vaccination program has driven a sharp drop in cervical cancer mortality, effectively eliminating deaths among the youngest women in reported cohorts. The findings underscore vaccine impact on prevention, bolster calls for broader uptake, and highlight a rare public‑health victory that actually lives up to the hype.
- England study: near-zero deaths in vaccinated young women (9)
- Scaling vaccines and screening: global equity and strategies (5)
England study: near-zero deaths in vaccinated young women
Scaling vaccines and screening: global equity and strategies
Rishabh Jain: What ALTAIR Teaches Us About ctDNA-Positive CRC
oncodaily - Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X: “ctDNA-positive CRC after curative surgery sounds like the perfect place to intervene. But ALTAIR says: not so fast. Phase 3, double-blind […]
AI Summary: Coverage examines ALTAIR, a randomized phase‑3 trial testing post‑adjuvant chemotherapy for patients with resected colorectal cancer who are ctDNA‑positive. Experts dissect trial design, endpoints and implications for ctDNA‑guided treatment decisions, debating whether circulating tumor DNA should steer adjuvant therapy or remain an elegant biomarker with stubborn practical hurdles.
E. Anders Kolb: Blood Cancer United Preserves Access to Luveltamab Tazevibulin for Children with AML
oncodaily - E. Anders Kolb, Chief Executive Officer of Blood Cancer United, shared a post on LinkedIn: “Today we announced a first‑of‑its‑kind intervention from a nonprofit. Blood Cancer United has stepped up […]
AI Summary: A nonprofit stepped into a supply crisis and purchased the remaining stock of an experimental agent to preserve access for children with acute myeloid leukemia. The emergency buy protects current patients from treatment interruption while stakeholders scramble for a durable manufacturing or regulatory fix, illustrating how charities sometimes act like pharma’s safety net.
Electronic cigarette use after smoking cessation and lung cancer risk
Yeon Wook Kim / nature - Nature Medicine, Published online: 08 June 2026; doi:10.1038/s41591-026-04469-5A nationwide retrospective analysis of 4.5 million Korean adults found that electronic cigarette use after smoking cessation was associated with higher lung cancer incidence an…
AI Summary: A new analysis finds people who turn to e‑cigarettes after quitting smoking may not be getting the safety upgrade they were promised. Researchers report that vaping post‑cessation is associated with increased lung disease markers and a raised risk profile for lung cancer, undermining harm‑reduction claims and prompting calls for caution and clearer guidance.
Ultrasensitive blood test predicts head and neck cancer relapse months earlier
medicalxpress - A new study by investigators from Mass General Brigham Cancer Institute has found that an ultrasensitive blood test called HPV-DeepSeek could help identify which people with HPV-associated head and neck cancer still had cancer cells in their bodies after …
AI Summary: Researchers validated an ultrasensitive HPV whole‑genome sequencing blood assay that detects minimal residual disease after surgery for HPV‑positive head and neck cancer, flagging relapse months before clinical signs. Early detection could enable earlier salvage therapy and closer surveillance, potentially changing follow‑up care and improving outcomes for this patient group.
Florian Lordick Elected ESMO President 2029–2030
oncodaily - Professor Florian Lordick has been elected President of the European Society for Medical Oncology for the 2029–2030 term, marking a new leadership chapter for one of the world’s leading oncology […]
AI Summary: Florian Lordick will serve as ESMO president for 2029–2030, pledging to prioritise precision oncology, workforce development and stronger European collaboration. Colleagues praise his vision for translating research into practice and amplifying policy advocacy; expectations include initiatives to close care gaps and bolster international partnerships — because someone has to herd this many oncologists.
Julie Gralow: Mobile App Symptom Monitoring Helps Maintain Quality of Life in Advanced Cancer
oncodaily - Julie Gralow, Chief Medical Officer of the American Society of Clinical Oncology, shared a post on X: “Use Of Mobile App For Proactive Symptom Monitoring Helped Patients With Advanced Cancer […]
AI Summary: A smartphone-based symptom monitoring program preserved quality of life for people with advanced cancer by enabling real‑time reporting and prompt clinician response. The intervention maintained patient function and well‑being compared with usual care, demonstrating a scalable, low‑cost way to keep symptoms under control — because yes, your phone can sometimes do what clinic schedules cannot.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer
oncodaily - The NRG-GY018 trial returned to the ASCO 2026 stage with the question that matters more than any progression endpoint: do patients actually live longer? Presented by Ramez N. Eskander, MD […]
AI Summary: Updated results from the NRG‑GY018 trial show adding pembrolizumab to chemotherapy sustains an overall survival benefit in advanced endometrial cancer. The follow‑up confirms the durability of immunotherapy’s impact and supports integrating checkpoint inhibitors into standard regimens for eligible patients, potentially changing practice for a cancer type that’s long hungered for better systemic options.